Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol

NEW YORK, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced it has received a...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials